GVAX Multiple Myeloma Vaccine is under clinical development by Chinook Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect GVAX Multiple Myeloma Vaccine’s likelihood of approval (LoA) and phase transition for Multiple Myeloma (Kahler Disease) took place on 28 Apr 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their GVAX Multiple Myeloma Vaccine Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

GVAX Multiple Myeloma Vaccine overview

The vaccine is under development for the treatment of newly diagnosed or relapsed multiple myeloma. The therapeutic candidate is administered through intradermal injection. It comprises of irradiated cell lines that are genetically modified to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF). The therapeutic candidate is based on GVAX cancer vaccine technology.

Chinook Therapeutics overview

Chinook Therapeutics, Inc (Chinook)., formerly Aduro BioTech Inc is a clinical-stage immunotherapy company that discovers, develops and commercializes therapies for the treatment of cancer. The company develops product candidates using proprietary technology platforms such as live, attenuated, double-deleted listeria, sting pathway activators; and B-select monoclonal antibodies to create immunotherapies for the treatment of cancers, infectious and autoimmune diseases. Its products are under development and are intended for the treatment of variety of cancers, including metastatic colorectal, multiple myeloma cancers, as well as other solid tumors and lymphomas. The company collaborates with various pharmaceutical companies to expand its products, and technology platforms. It has an operational presence in The Netherlands. Chinook is headquartered in Berkeley, California, the US.

Quick View GVAX Multiple Myeloma Vaccine LOA Data

Report Segments
  • Innovator
Drug Name
  • GVAX Multiple Myeloma Vaccine
Administration Pathway
  • Intradermal
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.